TY - JOUR
T1 - Behandelingen van actinische keratosen: een overzicht
AU - Kessels, J.
AU - Kelleners-Smeets, N.
AU - Mosterd, K.
PY - 2014
Y1 - 2014
N2 - Actinic keratosis (AK) is the most frequent premalignant skin disease in the Caucasian population. As stated in the Dutch guideline, AK is a major health problem, with approximately 1 million patients suffering from AK and 160.000 new patients diagnosed yearly in the Netherlands. Up to 25[%] of all persons older than 40 years will develop AK. Hence, it represents the second most frequent reason for patients to visit a dermatologist. It is thought that an AK may develop into squamous cell carcinoma (SCC), but how often this happens is not known. In the literature, the prevalence of PCC developing in a previously diagnosed AK ranges from 0.25 to 25[%]. In the Netherlands, 15.000 patients develop a SCC each year with an estimated number of 750 metastases. The presentation of AK ranges from solitary to multiple lesions. For solitary lesions, cryotherapy is the most frequently used therapy. It is effective and cheap. However, in case of multiple lesions, field treatment is advised. There is a number of treatment modalities suitable for field therapy, with variation in effect, costs and side effects. However, the current literature on this subject is diverse and in the current Dutch guideline for AK there are no clear recommendations. Hence, which treatment the patient will receive relies on the preference of the physician. At the moment 5-FU and MAL-PDT are the two most common treatments. Because AK is chronic, patients will often have multiple treatments during life. Therefore, long-term efficacy, costs and patient preferences are important when choosing a therapy.
AB - Actinic keratosis (AK) is the most frequent premalignant skin disease in the Caucasian population. As stated in the Dutch guideline, AK is a major health problem, with approximately 1 million patients suffering from AK and 160.000 new patients diagnosed yearly in the Netherlands. Up to 25[%] of all persons older than 40 years will develop AK. Hence, it represents the second most frequent reason for patients to visit a dermatologist. It is thought that an AK may develop into squamous cell carcinoma (SCC), but how often this happens is not known. In the literature, the prevalence of PCC developing in a previously diagnosed AK ranges from 0.25 to 25[%]. In the Netherlands, 15.000 patients develop a SCC each year with an estimated number of 750 metastases. The presentation of AK ranges from solitary to multiple lesions. For solitary lesions, cryotherapy is the most frequently used therapy. It is effective and cheap. However, in case of multiple lesions, field treatment is advised. There is a number of treatment modalities suitable for field therapy, with variation in effect, costs and side effects. However, the current literature on this subject is diverse and in the current Dutch guideline for AK there are no clear recommendations. Hence, which treatment the patient will receive relies on the preference of the physician. At the moment 5-FU and MAL-PDT are the two most common treatments. Because AK is chronic, patients will often have multiple treatments during life. Therefore, long-term efficacy, costs and patient preferences are important when choosing a therapy.
M3 - Article
SN - 0925-8604
JO - Nederlands Tijdschrift voor Dermatologie en Venereologie
JF - Nederlands Tijdschrift voor Dermatologie en Venereologie
IS - 9
ER -